Discovery Stage Partnering Terms and Agreements in Pharma and Biotech

Be the first to review this product

Availability: In stock

$3,495.00

Quick Overview

Provides comprehensive understanding and unprecedented access to the discovery stage partnering agreements entered into by the worlds leading biopharma companies.

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech
Publication date Mar 2015
Publisher Current Partnering
Number of pages 3,998 (including appendices)
Report edition 6
Product code CP2056
ISBN n/a
Product type Research report
Available formats PDF, CD-ROM

* Required Fields

$3,495.00

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

 

This report contains over 3,000 links to online copies of actual discovery stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of discovery stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery stage compounds/products.

                                                   

Chapter 3 provides an overview of discovery stage deals strategy and deal structure including numerous case studies, whilst Chapter 4 gives an overview of the various payment strategies used in discovery stage deals.

 

Chapter 5 provides a review of discovery stage deal making since 2010. Deals are listed by headline value, signed by big pharma, big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 6 provides a detailed analysis of discovery stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.

 

Chapter 7 presents a review of the leading discovery stage deal by headline value.

                                        

Chapter 8 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 9 provides a comprehensive and detailed review of discovery stage partnering deals signed and announced since 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

A comprehensive directory of discovery stage partnering deals since 2010 forms Chapter 10.

 

The report also includes numerous tables and figures that illustrate the trends and activities in discovery stage partnering and deal making since 2010.

 

In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery stage products and compounds.

Discovery Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

 

  •  In-depth understanding of discovery stage deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 3,000 discovery stage deals together with contract documents if available
  • Detailed access to actual discovery stage deals entered into by the leading fifty big pharma and big biotech companies along with other biopharma companies
  • Analysis of the structure of discovery stage agreements with numerous real life case studies
  • Identify leading discovery stage deals by value since 2010
  • Identify the most active discovery stage dealmakers since 2010
  • Full listing of discovery stage deals by company A-Z, phase of development, deal type, therapy and technology focus
  • Understand the key deal terms companies have agreed in previous deals          
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Why do companies partner at discovery stage?

 

2.1. Introduction

2.2. The role of discovery stage partnering

2.2.1. In-licensing at discovery stage

2.2.2. Out-licensing at discovery stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into discovery stage partnering deals

2.4.1. Licensors reasons for entering discovery stage deals

2.4.2. Licensees reasons for entering discovery stage deals

2.5. The future of discovery stage partnering deals

 

Chapter 3 – Discovery stage deal strategies and structure

 

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical/biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study: LEO Pharma - 4SC

3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

3.2.1.1.c. Case study: Incyte – Agenus Bio

3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study: Servier – GeNeuro

3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

3.2.2.1.c. Case study: AstraZeneca - Ardelyx

3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on discovery, preclinical and clinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study : Pfizer – Spark Therapeutics

3.6.1.b. Case study : Contrafect – Trellis Bioscience

3.7. Multicomponent discovery stage partnering agreements

3.7.1.a. Example multicomponent early stage clauses

3.7.1.a. Case study: Tracon –Boehringer Ingelheim – Macrogenics

3.7.1.b. Case study: Fibrocell Science – Intrexon

 

Chapter 4 – Discovery stage partnering payment strategies

 

4.1. Introduction

4.2. Discovery stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

 

Chapter 5 – Trends in discovery stage deal making

 

5.1. Introduction

5.2. Discovery stage partnering over the years

5.2.1.. Attributes of discovery deals

5.3. Big pharma discovery stage dealmaking activity

5.4. Big biotech discovery stage dealmaking activity

5.5. Discovery stage partnering by deal type

5.6. Discovery stage partnering by disease type

5.7. Discovery stage partnering by technology type

 

Chapter 6 – Average payment terms for discovery stage partnering

 

6.1. Introduction

6.2. Guidelines for discovery stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Discovery stage payment terms – deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Discovery stage headline values

Figure 17: Discovery stage deals with a headline value- 2010

Figure 18: Discovery stage deals with a headline value- 2011

Figure 19: Discovery stage deals with a headline value- 2012

Figure 20: Discovery stage deals with a headline value- 2013

Figure 21: Discovery stage deals with a headline value- 2014

Figure 22: Discovery stage deals with a headline value- 2015

Figure 23: Discovery stage deal headline value distribution, US$million

Figure 24: Summary median headline value for discovery stage of development, 2010-2015

6.4.2. Discovery stage upfront payments

Figure 25: Discovery stage deals with upfront payment values– 2010

Figure 26: Discovery stage deals with upfront payment values- 2011

Figure 27: Discovery stage deals with upfront payment values- 2012

Figure 28: Discovery stage deals with upfront payment values- 2013

Figure 29: Discovery stage deals with upfront payment values- 2014

Figure 30: Discovery stage deals with upfront payment values- 2015

Figure 31: Discovery stage deal upfront payment distribution, US$million

Figure 32: Summary median upfront payments discovery stage of development, 2010-2015

6.4.3. Discovery stage milestone payments

Figure 33: Discovery stage deals with milestone payments -2010

Figure 34: Discovery stage deals with milestone payments -2011

Figure 35: Discovery stage deals with milestone payments -2012

Figure 36: Discovery stage deals with milestone payments -2013

Figure 37: Discovery stage deals with milestone payments -2014

Figure 38: Discovery stage deals with milestone payments -2015

Figure 39: Discovery stage deal milestone distribution, US$million

6.4.4. Discovery stage royalty rates

Figure 40: Discovery stage deals with royalty rates, %- 2010

Figure 41: Discovery stage deals with royalty rates, %- 2011

Figure 42: Discovery stage deals with royalty rates, %- 2012

Figure 43: Discovery stage deals with royalty rates, %- 2013

Figure 44: Discovery stage deals with royalty rates, %- 2014

Figure 45: Discovery stage deals with royalty rates, %- 2015

Figure 46: Discovery stage deal royalty rate distribution, US$million

Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015

 

Chapter 7 – Leading discovery stage deals

 

7.1. Introduction

7.2. Top discovery stage deals by value

 

Chapter 8 – Big pharma and big biotech discovery stage partnering deals

 

8.1. Introduction

8.2. How to use big pharma/big biotech discovery stage partnering deals

8.3. Big pharma discovery stage partnering company profiles

8.4. Big biotech discovery stage partnering company profiles

 

Chapter 9 – Discovery stage partnering contracts directory

 

9.1. Introduction

9.2. Company A-Z

9.3. By deal type

9.4. By therapy area

 

Chapter 10 – Discovery stage dealmaking directory by year

 

10.1. Introduction

10.2. Discovery stage deals - 2010

10.3. Discovery stage deals - 2011

10.4. Discovery stage deals - 2012

10.5. Discovery stage deals - 2013

10.6. Discovery stage deals - 2014

10.7. Discovery stage deals - 2015

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Upgrades to subscription access products

Order Form – Reports

 

View the accompanying volume for:  

 

Appendices

Introduction

Appendix 1 – Directory of discovery stage deals by company A-Z 2010-2015     

Appendix 2 – Directory of discovery stage deals by deal type 2010-2015

Appendix 3 – Directory of discovery stage deals by therapy area 2010-2015

Appendix 4 – Partnering resource center          

Online partnering         

Partnering events        

Further reading on dealmaking

 

Table of figures

 

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

Figure 2: Agreements signed by phase of development (2010-2015), % of all deals where stage disclosed

Figure 3: Components of the pure licensing deal structure

Figure 4: Payment options for discovery stage partnering deals

Figure 5: Issues affecting royalty rates

Figure 6: Discovery stage partnering frequency 2010-2015

Figure 7: Big pharma – top 50 – discovery stage deals 2010 to 2015

Figure 8: Big pharma discovery stage deal frequency – 2010 to 2015

Figure 9: Big biotech – top 50 – discovery stage deals 2010 to 2015

Figure 10: Big biotech discovery stage deal frequency – 2010 to 2015

Figure 11: Discovery stage partnering by deal type since 2010

Figure 12: Discovery stage partnering by disease type since 2010

Figure 13: Discovery stage partnering by technology type since 2010

Figure 14: Review of median upfront payments for discovery stage deals

Figure 15: Review of median milestone payments for discovery stage deals

Figure 16: Review of median royalty payments for discovery stage deals

Figure 17: Discovery stage deals with a headline value- 2010

Figure 18: Discovery stage deals with a headline value- 2011

Figure 19: Discovery stage deals with a headline value- 2012

Figure 20: Discovery stage deals with a headline value- 2013

Figure 21: Discovery stage deals with a headline value- 2014

Figure 22: Discovery stage deals with a headline value- 2015

Figure 23: Discovery stage deal headline value distribution, US$million

Figure 24: Summary median headline value for discovery stage of development, 2010-2015

Figure 25: Discovery stage deals with upfront payment values– 2010

Figure 26: Discovery stage deals with upfront payment values- 2011

Figure 27: Discovery stage deals with upfront payment values- 2012

Figure 28: Discovery stage deals with upfront payment values- 2013

Figure 29: Discovery stage deals with upfront payment values- 2014

Figure 30: Discovery stage deals with upfront payment values- 2015

Figure 31: Discovery stage deal upfront payment distribution, US$million

Figure 32: Summary median upfront payments discovery stage of development, 2010-2015

Figure 33: Discovery stage deals with milestone payments -2010

Figure 34: Discovery stage deals with milestone payments -2011

Figure 35: Discovery stage deals with milestone payments -2012

Figure 36: Discovery stage deals with milestone payments -2013

Figure 37: Discovery stage deals with milestone payments -2014

Figure 38: Discovery stage deals with milestone payments -2015

Figure 39: Discovery stage deal milestone distribution, US$million

Figure 40: Discovery stage deals with royalty rates, %- 2010

Figure 41: Discovery stage deals with royalty rates, %- 2011

Figure 42: Discovery stage deals with royalty rates, %- 2012

Figure 43: Discovery stage deals with royalty rates, %- 2013

Figure 44: Discovery stage deals with royalty rates, %- 2014

Figure 45: Discovery stage deals with royalty rates, %- 2015

Figure 46: Discovery stage deal royalty rate distribution, US$million

Figure 47: Summary median royalty rate for discovery stage of development, 2010-2015

Figure 48: Top discovery stage deals that exceeds $1 billion in deal value since 2010

 

For the full list of companies mentioned in the report, please contact enquiry@currentpartnering.com 

Pricing options

  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license

 

A full explanation of license type definitions can be found here.

 

An additional $500 per copy will be added for CD-ROM.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

Product Tags

Other people marked this product with these tags:

Use spaces to separate tags. Use single quotes (') for phrases.

© 2015 Wildwood Ventures Ltd.